

Promoting Continuous Manufacturing in the Pharmaceutical Sector

The Brookings Institution • Washington, DC

October 19, 2015

8:30 a.m. Registration

9:00 a.m. Welcome, Overview, and Meeting Objectives

Mark McClellan, Senior Fellow and Director, Health Care Innovation and Value Initiative, The Brookings Institution

Greg Daniel, Fellow and Managing Director, Center for Health Policy, The Brookings Institution

9:15 a.m. Promoting the Adoption of Continuous Manufacturing in the Pharmaceutical Industry: the FDA perspective

Janet Woodcock, Director, Center for Drug Evaluation and Research, US Food and Drug Administration

9:30 a.m. Session I: Assessing the Current Landscape and Future Direction for Continuous Manufacturing

Mark McClellan, *Moderator*

Panelists:

- Lawrence Yu, Deputy Director, Office of Pharmaceutical Quality, US Food and Drug Administration
- Fernando Muzzio, Director, Center for Structured Organic Particulate Systems, & Distinguished Professor, Chemical and Biochemical Engineering, Rutgers University
- Alastair Florence, Professor of Pharmaceutical Science & Director, EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde
- Markus Krumme, Head of the Continuous Manufacturing Unit, Novartis Pharmaceuticals
- Konstantin Konstantinov, Vice President, Late Stage Process Development, Sanofi

10:30 a.m. Break

10:45 a.m. Session II: Improving Scientific and Technical Knowledge to Support Continuous Manufacturing

Mark McClellan, *Moderator*

Panelists:

- Mel Koch, Principle Scientist, Center for Process Analysis and Control (CPAC), University of Washington
- Richard Braatz, Edwin R. Gilliland Professor of Chemical Engineering, Massachusetts Institute of Technology

- Michael O'Brien, Senior Vice President, Global Science, Technology and Commercialization, Pfizer
- Eliana Clark, Vice President, Global Manufacturing Sciences, Biogen
- Eugene Choi, Technical Advisor to the Defense Advanced Research Projects Agency, Strategic Analysis, Inc.

12:00 p.m. Lunch

1:00 p.m. Session III: Addressing Barriers to the Adoption of Continuous Manufacturing
Greg Daniel, *Moderator*

Panelists:

- Patricia Hurter, SVP, Global Pharmaceutical Development, Vertex
- Frank Montgomery, Global Head, Regulatory CMC, AstraZeneca
- Johannes Khinast, Head of the Institute of Process and Particle Engineering, & Scientific Director, Research Center of Pharmaceutical Engineering (RCPE), Graz University of Technology
- Robin Robinson, Director, Biomedical Advanced Research and Development Authority, & Deputy Assistant Secretary for Preparedness & Response, US Department of Health and Human Services

2:30 p.m. Break

2:45 p.m. Session IV: Building Stakeholder Collaborations to Facilitate the Implementation of Continuous Manufacturing
Greg Daniel, *Moderator*

Panelists:

- Clive Badman, Head of Pre-Competitive Collaboration, GSK
- Liam Feely, Vice President, Manufacturing Science & Technology, AbbVie
- Gintaras Reklaitis, Burton and Kathryn Gedge Distinguished Professor of Chemical Engineering, Purdue University
- Seongkyu Yoon, Assistant Professor of Chemical Engineering, University of Massachusetts at Lowell
- Keith Roper, Program Director, Engineering Research Centers, National Science Foundation

3:45 p.m. Closing Remarks
Greg Daniel

4:00 p.m. Adjournment

Convened by the Center for Health Policy at Brookings and supported by a cooperative agreement with the U.S. Food and Drug Administration.